Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Kolon TissueGene shifts to sole leadership as No resigns after TG-C setback

21 September 2026 · By · Wire by Fusion42

Published

21 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

South Korea

◆ Source

Read at biz.chosun.com →

◆ Verified

Fusion42 · 21 September 2026 · Fusion42 review

Kolon TissueGene CEO No Moon-jong resigned following the failure of TG-C, an osteoarthritis gene therapy, to meet primary endpoints in a US phase 3 trial, with Jeon Seung-ho becoming sole CEO and continuing development efforts.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face tighter scrutiny on trial management in biotech after a company's lead resigns over a key drug's failed US trial. Proper trial oversight is now more crucial for your market access.

◆ Coverage

1 source · 21 Sep 2026

◆ Related on Wire

◆ Topics

Biotechleadership-changeclinical-trialgene-therapyosteoarthritisbiotech-development